-
Innovation Ranking
NewInnovation Ranking – Nektar Therapeutics
Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of a wide range of molecules including large classes of drugs targeting numerous disease areas. The company’s products focus on various disease areas including cancer, pain, infections, and immunology among others. Its research and development involve peptides, proteins,...
-
Product Insights
NewNet Present Value Model: Nektar Therapeutics’s Rezpegaldesleukin
Empower your strategies with our Net Present Value Model: Nektar Therapeutics's Rezpegaldesleukin report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Nektar Therapeutics Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Nektar Therapeutics Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewNet Present Value Model: GSK plc’s Depemokimab
Empower your strategies with our Net Present Value Model: GSK plc's Depemokimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Arvinas Inc’s Bavdegalutamide
Empower your strategies with our Net Present Value Model: Arvinas Inc's Bavdegalutamide report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Teverelix in Hormone-Sensitive Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Teverelix in Hormone-Sensitive Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Teverelix in Hormone-Sensitive Prostate Cancer Drug Details: Long acting formulation...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Solid Tumor Drug Details: NKTR-255 is under development for...